Back to Search
Start Over
The aromatase inactivator 4-hydroxyandrostenedione (4-OH-A) inhibits tamoxifen metabolism by rat hepatic cytochrome P-450 3A: potential for drug-drug interaction of tamoxifen and 4-OH-A in combined anti-breast cancer therapy.
- Source :
-
Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 1999 Mar; Vol. 27 (3), pp. 389-94. - Publication Year :
- 1999
-
Abstract
- Tamoxifen (tam), an anti-breast cancer agent, is metabolized into tam-N-oxide by the hepatic flavin-containing monooxygenase and into N-desmethyl- and 4-hydroxy-tam by cytochrome P-450s (CYPs). Additionally, tam is metabolically activated by hepatic CYP3A, forming a reactive intermediate that binds covalently to proteins. Tam and 4-hydroxyandrostenedione (4-OH-A) are currently used to treat breast cancer, and it has been contemplated that 4-OH-A be given concurrently with tam to contravene potential tumor resistance to tam. Because alterations in tam metabolism may influence its therapeutic efficacy, the effect of 4-OH-A on tam metabolism was examined. Incubation of tam with liver microsomes from phenobarbital-treated rats, in the presence of 4-OH-A (10-100 microM), resulted in marked inhibition of tam-N-demethylation and tam covalent binding and in decreased tam-N-oxide accumulation; however, there was no inhibition of the formation of 4-hydroxy-tam and of 3,4-dihydroxytamoxifen. These findings indicate that 4-OH-A inhibits CYP3A, but not P-450(s) that catalyze tam 4-hydroxylation. The diminished tam-N-oxide accumulation could be due to decreased N-oxide formation and/or due to increased N-oxide reduction. Incubation of tam-N-oxide with liver microsomes containing heat-inactivated flavin-containing monooxygenase demonstrated that 4-OH-A increases the accumulation of tam, possibly by diminishing its P-450-mediated metabolism. Kinetic studies indicate that 4-OH-A is a competitive inhibitor of CYP3A, but not a time-dependent inactivator. Consequently, the concurrent treatment of tam and 4-OH-A may result in increased tam half-life and thus could potentiate the therapeutic efficacy of tam and diminish the potential side effects of tam by inhibiting its covalent binding to proteins and possibly to DNA.
- Subjects :
- Androstenedione pharmacology
Animals
Antineoplastic Agents, Hormonal metabolism
Antineoplastic Agents, Hormonal pharmacokinetics
Antineoplastic Combined Chemotherapy Protocols pharmacology
Aromatase metabolism
Breast Neoplasms drug therapy
Cytochrome P-450 CYP3A
Drug Interactions
Enzyme Activation drug effects
Liver metabolism
Male
Rats
Rats, Sprague-Dawley
Tamoxifen metabolism
Tamoxifen pharmacokinetics
Androstenedione analogs & derivatives
Antineoplastic Agents pharmacology
Antineoplastic Agents, Hormonal antagonists & inhibitors
Aromatase Inhibitors
Aryl Hydrocarbon Hydroxylases
Cytochrome P-450 Enzyme System metabolism
Liver drug effects
Liver enzymology
Oxidoreductases, N-Demethylating metabolism
Tamoxifen antagonists & inhibitors
Subjects
Details
- Language :
- English
- ISSN :
- 0090-9556
- Volume :
- 27
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Drug metabolism and disposition: the biological fate of chemicals
- Publication Type :
- Academic Journal
- Accession number :
- 10064571